A neuropsychobiological approach to optimize patient selection for GLP-1-based pharmacotherapy for weight management across the binge eating spectrum

Overview

Sponsor-declared trial summary

Key facts

Sponsor

UZ Leuven

Participant type

Patients

Age range

18-64 years

Gender

Male and Female

Therapeutic area

Diseases [C] - Nutritional and Metabolic Diseases [C18]

Decision date (initial)

2026-06-08

Transition trial

No

Low-intervention

No

Rare-disease indication

No

Vulnerable population

No

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Efficacy

To identify for whom semaglutide works best.

Secondary objectives 3

1. To investigate how semaglutide works.
2. To examine whether semaglutide’s psychobiological mechanisms of action differ along the BE spectrum.
3. To develop a multivariate prediction model for successful weight and BE severity reduction in patients with obesity across the BE spectrum.

Conditions and MedDRA coding

obesity

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 4

1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
2. At least 18 years of age and under 65 years of age at the time of signing the informed consent form (ICF)
3. Use of highly effective methods of birth control; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner.
4. BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with at least one weight-related comorbidity

Exclusion criteria 19

1. Any form of diabetes mellitus (T1- or T2DM), defined as current hemoglobin A1c (HbA1c) > 6.5% or the use of antihyperglycemic drugs (metformin is permitted if prescribed for an indication other than T2DM and at a stable dose for at least 3 months days prior to screening)
2. Use of incretin-based drugs, including GLP-1RAs (including dual agonists) and dipeptidyl peptidase-4 (DPP-4) inhibitors or amylin analogues within 3 months prior to screening
3. Contraindications for semaglutide: history of pancreatitis, medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2)
4. Chronic kidney disease 3b or worse, defined as estimated Glomerular Filtration Rate (eGFR) < 45 ml/min/1.73m²
5. Previous bariatric surgery
6. Disorders known to affect DA signaling significantly, including movement disorders such as Parkinson’s disease, prolactinoma, paraganglioma, pheochromocytoma.
7. Active use of medication affecting DA signaling, including antiparkinson medications, attention deficit hyperactivity disorder (ADHD) medications, antipsychotics, naltrexone-bupropion for weight management or antidepressants; use of serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), or trazodone is permitted if participants are on a stable dose for at least three months. Incidental use of antiemetics or sedative hypnotics is allowed but not within 48 hours prior to a study visit.
8. Current or recent (within the past 6 months) clinically significant alcohol or drug misuse (excluding nicotine) that, in the investigator’s judgment, may compromise participant safety or the integrity of study data.
9. Active severe neuropsychiatric disorders, including dementia, psychotic disorder, bipolar disorder and severe depression
10. Acute suicidality or history of suicide attempt within 5 years prior to screening
11. Any condition or major illness which, in the investigator’s opinion, may jeopardise participant safety or compliance with the protocol
12. Unable to understand the risks, realistic benefits and compliance requirements of each program
13. Unwillingness to be informed about incidental findings that may be important for the participant’s health
14. Recent participation (< 30 days) or simultaneous participation in an interventional Trial with an investigational medicinal product (IMP) or device
15. If applicable: Female who is pregnant, breast-feeding or intends to become pregnant in the following 6 months or is of childbearing potential and not using an adequate, highly effective contraceptive
16. For PET scanning (subset n=64): exposure to a significant amount (> 1mSv) of ionizing radiation in other research studies within the last 12 months
17. For MRI scanning: any condition that would interfere with MRI scanning (e.g., cochlear implant, metal fragments in the eyes, cardiac pacemaker, neural stimulator and metallic body inclusion or other metallic implants in the body which may interfere with MRI scanning)
18. Claustrophobia or too much uneasiness in limited spaces (to tolerate confinement during scanning procedures)
19. Severe back problems, interfering with lying in supine position in the scanner without movement for long durations

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 2

1. Change in BMI after semaglutide treatment (baseline vs at 6 months of semaglutide treatment)
2. Change in Binge Eating Scale (BES) score after semaglutide treatment (baseline vs at 6 months of semaglutide treatment)

Secondary endpoints 3

1. Change in waist/hip ratio after semaglutide treatment (baseline vs at 6 months of semaglutide treatment)
2. Change in body composition after semaglutide treatment (baseline vs at 6 months of semaglutide treatment)
3. Changes in the following after semaglutide treatment (baseline vs at 6 months of semaglutide treatment): Gut hormone blood levels; Blood and urinary DA levels; Appetite-related sensations; DA release in the brain in response to food reward; Neural responses to food reward; Food liking, wanting, and craving; Emotional state; HR and HRV; BP; Chronic hair cortisol levels; SCFA blood levels; Cytokine blood levels; BBB/BSCFB integrity/permeability; Neuroinflammation

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

UZ Leuven

Sponsor organisation

UZ Leuven

Address

Herestraat 49

City

Leuven

Postcode

3000

Country

Belgium

Scientific contact point

Organisation

UZ Leuven

Contact name

Roman Vangoitsenhoven

Public contact point

Organisation

UZ Leuven

Contact name

Roman Vangoitsenhoven

Third parties 1

Locations

1 EU/EEA country · 1 investigational sites

By country

Investigational sites

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 20 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

1 submissions — initial application plus substantial / non-substantial modifications